Medicare_Claims_Processing_Manual / Change_Request_5124

Why This Topic Matters

The update affects how certain PET scan claims are reported and processed under Medicare, especially for services tied to approved clinical trials and coverage determinations. Understanding the scope helps organizations route claims correctly and align documentation with current CMS instructions.

Article Sections

1. CMS Transmittal 956 / Change Request 5124 Overview

   Introduces the CMS transmittal, timing, and the manual changes associated with PET scan billing in approved clinical trial settings. Summarizes the general scope of the update and affected manual sections.

2. General Information and Background

   Provides background on PET imaging, the CMS coverage framework, and the types of clinical studies referenced by the update. Also outlines the broader clinical trial context for the policy.

3. PET, Alzheimer’s Disease, and Dementia

   Describes the CMS-approved clinical trial context for dementia and neurodegenerative disease PET services and the related claims-processing update. Addresses the transition from prior instructions to the revised reporting approach.

4. Policy

   Summarizes the revised billing and claims-processing policy for PET scans performed under CMS-approved clinical trials. Discusses the affected service categories and the claim-processing framework for carriers and fiscal intermediaries.

5. 60.12 - Coverage for PET Scans for Dementia and Neurodegenerative Diseases

   Presents the manual section covering PET scan services for dementia and neurodegenerative disease, including the claim documentation and billing context. Includes related diagnosis and documentation considerations referenced by the manual.

6. 60.15 - Billing Requirements for CMS-approved Clinical Trial Claims for PET Scans for Neurodegenerative Diseases, Previously Specified Cancer Indications, and All Other Cancer Indications Not Previously Specified

   Outlines the billing requirements for PET scan claims tied to CMS-approved clinical trials across neurodegenerative and cancer indications. Focuses on the carrier and FI claim-processing framework described in the manual update.